William Blair says Applied Therapeutics (APLT)’ complete response letter from the FDA for govorestat for the treatment of galactosemia is “unexpected and disappointing.” Given the lack of information ...

Chip and crypto stocks rose, while Applied Therapeutics fell sharply after FDA denial. This image is AI-generated and does ...

Retailers are in focus with an expected surge in shoppers, while other market movements include crypto gains and a plunge in ...

Applied Therapeutics' stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat ...

Applied Therapeutics ( APLT, Financials) announced that the U.S. Food and Drug Administration issued a Complete Response ...

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...

RBC Capital Markets downgraded Applied Therapeutics Inc (NASDAQ:APLT) stock to "sector perform" from "outperform” citing ...

Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...

FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for ...

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company focused on rare diseases, saw a significant drop in its stock price following the recent news that the U.S. Food ...

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...